MIAI-Vaccine

Accelerate Discovery with MIAI-Vaccine’s Precision Computational Platform

The MIAI-Vaccine project was developed at Ulster University during the COVID-19 pandemic alongside the global effort to quickly develop vaccine candidates. Since 2020, the team has been developing a computational platform to produce peptide-based vaccine candidate sequences for COVID-19 and other viruses, such as Human Bocavirus and Ebola virus.

The Problem

Traditional vaccine development is hindered by lengthy and costly trial-and-error processes, often resulting in delayed responses to emerging infectious diseases. Biotechnology and pharmaceutical companies face immense pressure to rapidly deliver safe and effective vaccines to combat global health threats like COVID-19. However, the lack of efficient tools for generating and evaluating vaccine candidates impedes progress, leading to missed opportunities to save lives and contain outbreaks.

Our Solution

Watch the short explainer video below to find out how MIAI-Vaccine aims to solve the problem.

Value Proposition

The service we will provide to our customers will swiftly generate peptide-based vaccine candidates for various infectious diseases, including COVID-19. Our computational pipeline meticulously evaluates candidate peptides for antigenicity, allergenicity, autoimmunity, and immunogenicity, ensuring safety and efficacy, and generates personalized vaccine candidates following Personalized Medicine principles. With our comprehensive analysis, we empower our customers to accelerate vaccine development, saving time and resources while addressing global health challenges.



Pharmaceutical and biotechnology companies

Our potential target customers are pharmaceutical and biotechnology companies involved in peptides and vaccine development. These innovative companies seek efficient solutions to accelerate their vaccine discovery process while ensuring safety and efficacy. By utilizing our computational platform, they can expedite the generation and evaluation of vaccine candidates, ultimately advancing their research and contributing to global health initiatives.



Healthcare providers and patients

Ultimately the end users of our products will be healthcare providers and patients. Healthcare providers rely on safe and effective vaccines to protect their patients from infectious diseases. Patients could ultimately benefit from access to timely and effective vaccines. The timely availability of vaccines can help mitigate the spread of diseases within communities, reducing the risk of outbreaks and safeguarding public health.